Telescope Innovations Corp · CSE:TELI
Telescope Innovations — Investor Presentation (July 2024)
26 slides from Telescope Innovations's investor presentation, Jul 19, 2024
Slide 1: Fewer Experiments. More Insight.
FEWER EXPERIMENTS. MORE INSIGHT.
Slide 2: Disclaimer and forward-looking statements
TELI (CSE) The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, acc
Slide 3: Our Company
TELI (CSE) OUR COMPANY TELIF (OTCQB) We build intelligent automation platforms that accelerate chemical process development. ARTIFICIAL ADVANCED AUTOMATION & PROCESS INTELLIGENCE ANALYTICAL TECHNOLOGY ROBOTICS DEVELOPMENT Telescope reduces R&D, manufacturing, and commercial deployment costs for the
Slide 4: Who We Are
TELI (CSE) WHO WE ARE Our award-winning scientific leadership includes a 2-time Nobel Prize Winner in Chemistry. TELIF (OTCQB) We have collectively authored over 450 academic publications and 34 patents. PROF. JASON HEIN DR. BARRY SHARPLESS HENRY DUBINA DR. JEFF SHERMAN JOHN KIRINCIC CTO AND DIRECTOR
Slide 5: Our Board of Directors
TELI (CSE) OUR BOARD OF DIRECTORS Our directors bring over 80 years combined experience in building technology companies and TELIF (OTCQB) successfully managing companies in the capital markets. DR. ANDY ROBINSON ROBERT MINTAK ALI PEJMAN PROF. JASON HEIN HENRY DUBINA An experienced scientist with a
Slide 6: Our Vision
OUR VISION 1 2 3 International leadership in online Provider-of-choice for Global deployment in chemical and chemistry sampling and analysis products Self-Driving Laboratories pharmaceutical process development telescopeinnovations.com 6
Slide 7: Our Business Model: Technology Development
TELI (CSE) OUR BUSINESS MODEL: TECHNOLOGY DEVELOPMENT WORLD-CLASS TELIF (OTCQB) SCIENTISTS We’ve collectively authored over 450 academic publications and 34 patents. New IP enriches our team and partnerships. R&D WITH NEW MARKET-DRIVEN IP PRODUCT STRATEGIC & KNOW-HOW DEVELOPMENT INDUSTRIAL CLIENTS A
Slide 8: Combining Experienced Business and Technical Management to Build Enterprise Value
TELI (CSE) COMBINING EXPERIENCED BUSINESS AND TECHNICAL MANAGEMENT TO BUILD ENTERPRISE VALUE TELIF (OTCQB) World-class scientific leadership built Telescope’s $15 M enterprise value through R&D with strategic industrial clients. Telescope is ideally positioned for long-term growth with strong EBITDA
Slide 9: Our Vision
OUR VISION 1 2 3 International leadership in online Provider-of-choice for Global deployment in chemical and chemistry sampling and analysis products Self-Driving Laboratories pharmaceutical process development telescopeinnovations.com 9
Slide 10: Flagship Product: DirectInject-LC
TELI (CSE) FLAGSHIP PRODUCT A process analytical technology for TELIF (OTCQB) automated analysis of chemical reactions, DIRECTINJECT - LC™ globally distributed by METTLER TOLEDO Since launch in late 2022, units are deployed at 13 of the top 20 pharma “...automation, lab digitization, companies in th
Slide 11: Flagship Product: Mettler Toledo Global Distribution Partner
TELI (CSE) FLAGSHIP PRODUCT : METTLER TOLEDO IS A HIGHLY INCENTIVIZED GLOBAL DISTRIBUTION PARTNER TELIF (OTCQB) MARKET NEED PORTFOLIO INNOVATION LC is a gold-standard analytical tool (used in >80% of New DirectInject-LC™ product energizes MT chemistry process research and manufacturing porftolio, en
Slide 12: Global Process Analytical Technology (PAT) Market
TELI (CSE) GLOBAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET* KEY TELIF (OTCQB) ● Massive, increasing R&D spending in pharma and biotech DRIVERS ● Need for automation and quality control in pharmaceutical manufacturing GLOBAL MARKET SIZE 2021 BREAKDOWN BY TECHNIQUE $4.3 B DirectInject-LC™ 4 addresse
Slide 13: Our Vision
OUR VISION 1 2 3 International leadership in online Provider-of-choice for Global deployment in chemical and chemistry sampling and analysis products Self-Driving Laboratories pharmaceutical process development telescopeinnovations.com 13
Slide 14: Self-Driving Labs Reduce Time and Costs of Commercializing New Chemistry
TELI (CSE) SELF-DRIVING LABS REDUCE THE TIME AND COSTS OF COMMERCIALIZING NEW CHEMISTRY & PHARMACEUTICALS TELIF (OTCQB) Traditional R&D loop Self-driving lab Planning by AI guided human-in-the-loop decision-making Manual analysis and Manual Automated analysis Robotically automated data interpretatio
Slide 15: Strong Investments in Self-Driving Laboratories (SDLs)
STRONG INVESTMENTS IN SELF-DRIVING LABORATORIES (SDLs) $CAD 500 M | 2023 £ 81 M | 2018 Acceleration Consortium $200 M: Largest Canadian federal research grant (CFREF) Materials Innovation Factory + $300 M: Matching by industry & academic partners SDLs combine robotics and AI to accelerate chemistry
Slide 16: Key Market Drivers for SDL Investment
KEY MARKET DRIVERS FOR SDL INVESTMENT ACCELERATED TIME-TO-MARKET FOR NEW CHEMICALS AND PROCESSES e.g. Industry demonstrated during the pandemic that new medications could be developed in 1-2 years vs. long held average of 10-12 years AI guided decision-making INCREASED COMPETITIVENESS WITH OFF-SHORE
Slide 17: Self Driving Lab Market Opportunity in Process R&D
TELI (CSE) SELF DRIVING LAB MARKET OPPORTUNITY IN PROCESS R&D TELIF (OTCQB) TELESCOPE SDL SALES PLAN SPECIALTY GOV’T & ($M USD) BIOPHARMA CRO / CDMO CHEM ACADEMIA Large companies investing 72 57 185 40 in lab automation Adoption rate of previous s personal lab automation 31 5.5 4 4 r v ice e systems
Slide 18: Our Vision
OUR VISION 1 2 3 International leadership in online Provider-of-choice for Global deployment in chemical and chemistry sampling and analysis products Self-Driving Laboratories pharmaceutical process development telescopeinnovations.com 18
Slide 19: Target Market Penetration
TELI (CSE) TARGET MARKET PENETRATION TELIF (OTCQB) Target industries share requirements for high manufacturing efficiency, accelerated R&D, & cost-effective processes. (Global market sizes shown in USD) CURRENT CLIENT TARGET MARKETS: 2-5 YEARS TARGET MARKETS: 5-10 YEARS BASE New products & services,
Slide 20: Strategic Partners and Clients
TELI (CSE) STRATEGIC PARTNERS AND CLIENTS TELIF (OTCQB) INSTRUMENTATION & PHARMACEUTICAL ENGINEERING & MINING GOVERNMENT TECHNOLOGY COMPANIES COMPANIES AND ACADEMIA PARTNERS telescopeinnovations.com 20
Slide 21: Building a Successful Track Record
TELI (CSE) BUILDING A SUCCESSFUL TRACK RECORD Repeat clients for TELIF (OTCQB) Self-Driving Labs in chemical and DIRECTINJECT - LC™ Second profitable pharmaceutical quarter closed deployed by 13 of top 20 pharma Global distribution manufacturing (Q3, FY2023) companies in the world partnership for DIR
Slide 22: Key Business Plan Elements for 2024 and 2025
TELI (CSE) KEY BUSINESS PLAN ELEMENTS FOR 2024 AND 2025 SAMPLING / ANALYSIS SELF-DRIVING CHEMICAL / PHARMA TELIF (OTCQB) PRODUCTS LABORATORIES PROCESS DEVELOPMENT Global distribution of Formalize consortium of key Maintain and expand process DIRECTINJECT - LC via market- pharma companies to fund res
Slide 23: Strong Growth in First Years, Positive Trend for FY 2024
TELI (CSE) STRONG GROWTH IN FIRST 2 YEARS, POSITIVE TREND TELIF (OTCQB) FOR FY 2024 ● Revenue-positive in first full fiscal year (FY 2022) ● Major developments in FY 2024: ○ Global Distribution Agreement signed with Market-leading vendor (Mettler Toledo AutoChem) for DirectInject-LC™ ○ Previous FY rev
Slide 24: Capitalization
TELI (CSE) CAPITALIZATION STOCK TICKER SYMBOLS TELIF (OTCQB) TELI (CSE), TELIF(OTCQB) CAPITAL STRUCTURE PRICE* NUMBER March 2024 Average Shares issued 53,665,569 Stock options $ 0.54 4,683,050 Warrants $ 0.75 2,439, 749 Fully diluted share position 60,788,368 Shares held by Directors / Officers - 13,
Slide 25: Comparables: Lab Instrumentation Companies
TELI (CSE) COMPARABLES: LAB INSTRUMENTATION COMPANIES TELIF (OTCQB) P/E EV/EBITDA EV/TTM Sales Avg: 30 Avg: 29 Avg: 5.2 Agilent Mettler- Oxford Perkin ThermoFisher AMETEK Bruker Danaher Sartorius AG Shimadzu Teledyne Waters Technologies Toledo Instruments Elmer Scientific telescopeinnovations.com 25
Slide 26: Thank You
THANK YOU Contact: investors@telescopeinn.com
Telescope Innovations — Investor Presentation (July 2024) on 6ix